Business
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the structural advantages of biologics—making them ideally suited to address traditionally "undruggable" protein–protein interactions and complex receptors, while opening new avenues for oral drug di
About this update from Viva Biotech Holdings
[{"type":"text","content":"SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the structural advantages of biologics—making them ideally suited to address traditionally "undruggable" protein–protein interactions and complex receptors, while opening new avenues for oral drug discovery. With global investment in peptide pipelines steadily increasing, cyclic peptides are becoming a therapeutic frontier of rising importance.","length":702,"tagName":"p"},{"type":"text","content":"As the latest session in the ongoing Viva BioInsights webinar series, Medicinal Chemistry for Cyclic Peptide Drug Discovery, featuring Dr. Kejia Ding, Executive Director of Chemistry, and moderated by Mr. Simon Bury, Vice President of Business Development. The webinar attracted strong global interest, offering in-depth perspectives on how medicinal chemistry shapes cyclic peptide drug discovery—highlighting both the opportunities and challenges of this modality, illustrated through case studies and Viva's integrated capabilities.","length":539,"tagName":"p"},{"type":"text","content":"Cyclic Peptides: Bridging Small Molecules and Biologics","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"Cyclic peptides are increasingly recognized as an attractive drug modality to tackle traditionally "undruggable" targets. They combine the oral potential of small molecules with the structural advantages of biologics, enabling new approaches for protein–protein interactions and complex receptors. At the same time, they present key challenges: oral bioavailability is not easily achieved, and stability and permeability must be carefully optimized with a clear medicinal chemistry strategy.","length":501,"tagName":"p"},{"type":"text","content":"Viva Biotech supports cyclic peptide discovery with in-house phage display and a DEL library of cyclic peptides, alongside AI-based methods for structure prediction, sequence redesign, and de novo design. Structure determination and prediction leverage NMR, X-ray crystallography, molecular-dynamics simulations, and deep-learning models...